Synergy Pharmaceuticals' Chief Scientific Officer to Give Plenary Lecture on Plecanatide and SP-333 at the 15th Annual TIDES

Synergy Pharmaceuticals' Chief Scientific Officer to Give Plenary Lecture on
Plecanatide and SP-333 at the 15th Annual TIDES Summit

NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.
(Nasdaq:SGYP), a developer of new drugs to treat patients with
gastrointestinal disorders and diseases, today announced its Chief Scientific
Officer, Kunwar Shailubhai, Ph.D., M.B.A., will give a plenary lecture on
"Plecanatide and SP-333, Guanylate Cyclase-C Agonists: A New Class of Drug
Candidates for Treatment of Gastrointestinal Disorders and Diseases," at The
15^th Annual TIDES Summit, May 12-15, at the Hynes Convention Center in
Boston, MA.

Guanylate cyclase-C (GC-C) agonists are rapidly emerging as new orally
administered drug candidates for treatment of multiple gastrointestinal (GI)
disorders and diseases. The lecture will discuss the role of uroguanylin, the
natural agonist of GC-C, in the normalization of GI physiology.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat patients with gastrointestinal disorders and diseases. Synergy's lead
proprietary drug candidate, plecanatide, is a synthetic analog of the natural
human peptide hormone, uroguanylin, and functions by activating the guanylate
cyclase-C (GC-C) receptor on epithelial cells of the GI tract. Synergy
completed positive Phase I and Phase II clinical trials in patients with
chronic idiopathic constipation (CIC). Detailed positive findings from its
large multicenter trial of plecanatide in patients with CIC are being
presented at Digestive Disease Week (DDW) in Orlando, FL and will be published
this year. Synergy is also developing plecanatide for the treatment of
irritable bowel syndrome with constipation (IBS-C), having initiated the first
trial in IBS-C patients in late 2012. Synergy's second GC-C agonist, SP-333,
is in clinical development for the treatment of ulcerative colitis (UC). The
first Phase I trial in healthy volunteers was recently completed. More
information is available at http://www.synergypharma.com.

CONTACT: Media Contact:
         Janet Skidmore
         Mobile (during DDW): 215-429-2917
         Office: 215-658-4915
         skidmorecomm@earthlink.net
        
         Investor Contact:
         Danielle Spangler
         The Trout Group
         Office: 646-378-2924
         synergy@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.